The Impact of the COVID-19 Pandemic on Patient Disparities in Long-Term Opioid Therapy.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 38740467.
- Also identified by DOI 10.3122/jabfm.2023.230359R1 and PMC identifier 12874994.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The COVID-19 pandemic disrupted how primary care patients with chronic pain received care. Our study sought to understand how long-term opioid therapy (LtOT) for chronic pain changed over the course of the pandemic overall and for different demographic subgroups. We used data from electronic health records of 64 primary care clinics across Washington state and Idaho to identify patients who had a chronic pain diagnosis and were receiving long-term opioid therapy. We defined 10-month periods in 2019 to 2021 as prepandemic, early pandemic and late pandemic and used generalized estimating equations analysis to compare across these time periods and demographic characteristics. We found a proportional decrease in LtOT for chronic pain in the early months of the pandemic (OR = 0.94, <i>P = .007</i>) followed by an increase late pandemic (OR = 1.08, <i>P = .002</i>). Comparing late pandemic to prepandemic, identifying as Asian or Black, having fewer comorbidities, or living in an urban area were associated with higher likelihood of being prescribed LtOT. The use of LtOT for chronic pain in primary care has increased from before to after the COVID-19 pandemic with racial/ethnic and geographic disparities. Future research is needed to understand these disparities in LtOT and their effect on patient outcomes.
Medical subject headings
- COVID-19
- Chronic Pain
- Analgesics, Opioid
- Healthcare Disparities
- Primary Health Care